Skip to main content

Pancreatic Cancer: Step by Step Forward

  • Chapter

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 177))

Abstract

With the diagnosis of pancreatic cancer, the majority of patients are faced with an unexpected tragedy. There is a persistently low rate of curability, a so-called case fatality rate of around 95%.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   159.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   209.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   209.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Oettle H, Post S, Neuhaus P, et al (2007) Adjuvant chemotherapy with gemcitabine versus observation in patients undergoing curative-intent resection of pancreatic cancer. A multicenter randomized controlled trial. JAMA 297:267–277

    Article  PubMed  CAS  Google Scholar 

  2. Moore MJ, Goldstein D, Hamm J, et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966

    Article  PubMed  CAS  Google Scholar 

  3. Cunningham D, Chau I, Stocken D, Davies C, Dunn J, Valle J, et al (2005) Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer 3:4 [Suppl]

    Google Scholar 

  4. Burris HA 3rd, Moore MJ, Andersen J, et al (1997) Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413

    PubMed  CAS  Google Scholar 

  5. Oettle H, Pelzer U, Stieler J, Hilbig A, Roll L, Schwaner I, Adler M, Detken S, Dörken B, Riess H (2005) Oxaliplatin/folinic acid/5-fluorouracil [24 h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). Clin Oncol 23:16S, abstr 4031

    Google Scholar 

  6. Riess H, Pelzer U, Stieler J, Schwaner I, Heil G, Görner M, Mölle M, Hilbig A, Dörken B, Oettle H (2007) A randomized second line trial in patients with gemcitabine refractory advanced pancreatic cancer—CONKO 003. J Clin Oncol 25:18S, abstr 4517

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Riess, H., Goerke, A., Oettle, H. (2008). Pancreatic Cancer: Step by Step Forward. In: Pancreatic Cancer. Recent Results in Cancer Research, vol 177. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-71279-4_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-71279-4_1

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-71266-4

  • Online ISBN: 978-3-540-71279-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics